GERD Treatment in Calgary: Beyond PPIs

This is not a page selling you a replacement for your PPI, your GP, or your gastroenterologist. The evidence base for gut-directed hypnotherapy in GERD is meaningfully smaller than the evidence base for IBS, and any honest summary has to say so up front. What this page does is map out the standard Calgary GERD pathway, explain the three different conditions that get folded under the GERD label, and show where a gut-brain therapy might reasonably be tried for the subgroup whose PPI trial has failed and whose workup points toward a functional or hypersensitivity component.

The intended reader is the Calgary patient who has done the standard pathway, has been told their endoscopy is normal or near-normal, has had limited or no benefit from a PPI trial, and is wondering what comes next. That is a real and underserved clinical population. It is also a population for whom honest framing matters more than enthusiasm.

Most Calgary GERD journeys start the same way. The patient presents to a family physician with heartburn, regurgitation, an acidic taste in the mouth, sometimes chest discomfort, sometimes chronic cough or globus. The GP runs through the standard differential, looks for red-flag features, and, in the absence of alarm signs, offers an empirical proton pump inhibitor trial. Pantoprazole, esomeprazole, or rabeprazole at standard dose for four to eight weeks. If symptoms remit, the working diagnosis is GERD and the conversation moves to longer-term acid-suppression management.

If symptoms persist, the next step is typically an upper endoscopy through the Alberta Health Services GI referral pathway. Wait times in Calgary for non-urgent endoscopy can stretch to several months depending on the referring GP, the triage category, and current capacity at Foothills, Rockyview, Peter Lougheed, South Health Campus, and the Calgary endoscopy clinics. Endoscopy looks for erosive esophagitis, Barrett's esophagus, peptic ulcer, eosinophilic esophagitis, hiatal hernia, and other structural findings. If endoscopy is normal or near-normal and symptoms continue, the next-line investigation is 24-hour ambulatory pH monitoring or pH-impedance monitoring, available in Calgary through the AHS GI services at Foothills and Rockyview.

That standard pathway works well for the patient population it was designed for. Patients with documented acid disease respond to acid suppression, and the workup catches the structural pathology that needs its own pathway. The published response rate for PPI therapy in typical GERD lands somewhere in the 60 to 70 percent range depending on the source, with higher response in erosive esophagitis and lower response in non-erosive presentations. That is a reasonable response rate. It is not a 100 percent rate, and the patients who fall in the non-responding portion are where the standard pathway starts to thin out.

The gap most Calgary patients hit looks like this. PPI failed or partially worked. Endoscopy was normal or showed only minor non-specific changes. They have been told to stay on the PPI long-term anyway, or to trial a different PPI, or to add an H2 blocker at night. Symptoms persist. The next conversation about pH monitoring, GI consultation, or alternative explanations either does not happen or happens slowly. Many patients in this position eventually stop pushing and accept ongoing low-grade symptoms as the new normal. Some end up reading about the gut-brain axis and start asking different questions.

Public health insurance in Alberta covers GP visits and specialist GI consultations under AHCIP. It does not cover hypnotherapy, dietitian work outside hospital settings, or most psychological therapies that are delivered outside an AHS program. That coverage shape pushes patients toward the medication-only end of the pathway by default, because that is the path of least friction within the public system. The functional GERD subgroup is the population most disadvantaged by that default, because medication is rarely the right primary lever for them.

What the Calgary pathway tends to miss

Three things, in practice. First, the diagnostic distinction between true GERD and functional GERD-pattern conditions is not always clearly explained to the patient before a long PPI run is started. Second, when PPIs fail, the pivot from acid-disease thinking to gut-brain-axis thinking is not part of the default GP workflow, even though the published gastroenterology literature has supported that pivot for over a decade. Third, the Alberta-specific access constraints around non-medication therapies (CBT, gut-directed hypnotherapy, psychogastroenterology services) mean that even patients whose presentation clearly points toward a gut-brain layer often have nowhere obvious within the public system to send them.

The single most important conceptual move in this entire space is recognising that the GERD label, as it is used in everyday clinical conversation, covers three quite different conditions. They share a clinical picture (heartburn, regurgitation, upper-chest discomfort, sometimes throat or respiratory symptoms) but they have different mechanisms, different diagnostic findings, and different treatment logics. Lumping them together is the source of most of the PPI-failure stories.

1. True GERD (gastroesophageal reflux disease)

Pathological acid exposure of the esophagus, demonstrable on 24-hour pH monitoring or implied by erosive esophagitis on endoscopy. The lower esophageal sphincter is allowing acidic stomach content to wash back into the esophagus more often or for longer than it should. Damage can be visible on endoscopy (erosive GERD) or absent with abnormal acid exposure still measurable (non-erosive reflux disease, NERD). This is the population PPIs were designed for, and most patients in this group get meaningful relief from acid suppression. Long-term management focuses on PPI dose optimisation, hiatal hernia management where present, lifestyle adjustments, and surveillance in Barrett's esophagus.

2. Functional heartburn

Typical GERD-pattern symptoms in the absence of pathological acid exposure, normal endoscopy, and symptoms that do not correlate with reflux events on pH-impedance monitoring. By Rome IV definition this is a disorder of esophageal gut-brain interaction. The mechanism is altered esophageal pain processing rather than acid disease. PPIs help these patients much less reliably because there is no pathological acid problem to suppress in the first place. Some patients do report partial PPI benefit, which is usually attributed to placebo effect, mild concomitant true acid contribution, or non-acid effects of the medication.

3. Reflux hypersensitivity

Normal endoscopy, normal physiologic acid exposure on pH monitoring, but symptoms that DO correlate with reflux events on the recording. The esophagus is hypersensitive: even normal, non-pathological refluxate triggers symptoms. Mechanistically this is closer to functional heartburn than to true GERD, and it also belongs to the disorders-of-gut-brain-interaction family. PPI response is similarly mixed. The practical difference between functional heartburn and reflux hypersensitivity matters for the GI specialist trying to characterise the patient precisely; for treatment logic, both conditions point toward the gut-brain layer and away from acid-suppression-only thinking.

The clinical implication for the Calgary patient sitting with a GERD label and disappointing PPI results: the right next question is not always "higher PPI dose" or "different PPI". The right next question is often "which of these three conditions am I actually dealing with?". That question is answered by completing the workup. Endoscopy if not done, pH monitoring if not done. The answer reshapes the treatment logic for the years that follow.

There is also a real overlap layer that complicates the picture. Many patients with true GERD also have a functional component, particularly after long-standing disease where the central nervous system has had years to amplify visceral signalling. In that overlap group, partial PPI response makes sense: the acid layer is being treated and the gut-brain layer is not. For these patients, the gut-brain work is additive to ongoing acid-suppression therapy rather than a replacement for it. This is also the group where the related concept of visceral hypersensitivity is most clinically useful, as the same nerve-sensitivity mechanism that drives IBS pain in the colon can be expressed in the esophagus.

The investigations themselves are reasonably standardised across Canadian centres, with some Calgary-specific access details worth knowing. The point of walking through them in detail is so that a patient considering hypnotherapy for functional GERD knows what should already be done before that conversation makes clinical sense.

GP empirical PPI trial

Standard first step. Four to eight weeks at a standard dose of pantoprazole 40 mg, esomeprazole 40 mg, rabeprazole 20 mg, omeprazole 20 mg, or equivalent, taken 30 to 60 minutes before the first meal of the day. Some GPs trial 8 to 12 weeks before calling the trial unsuccessful. A positive response is traditionally read as supportive of acid-related disease; a negative response should prompt either dose escalation, switch to a different PPI, or a pivot to endoscopy depending on symptom pattern and presence of any red-flag features.

Upper endoscopy (esophagogastroduodenoscopy)

Performed if PPI fails, if there are alarm features, or if the symptom pattern points toward something other than uncomplicated reflux. Endoscopy directly visualises the lining of the esophagus, stomach, and proximal duodenum, looks for erosive esophagitis, Barrett's metaplasia, peptic ulcer disease, eosinophilic esophagitis (which can mimic GERD with prominent dysphagia or food impaction), hiatal hernia, and rarer findings including malignancy. Biopsies are routinely taken when indicated. Endoscopy is performed at AHS sites in Calgary including Foothills Medical Centre, Rockyview General, Peter Lougheed, and South Health Campus, with additional capacity through community endoscopy clinics.

24-hour ambulatory pH and pH-impedance monitoring

The investigation that distinguishes true non-erosive reflux disease from functional heartburn and reflux hypersensitivity. A small catheter or wireless capsule records esophageal pH (and in pH-impedance studies, also non-acid liquid and gas reflux events) over 24 to 96 hours. The patient logs symptoms in real time so that symptom-reflux correlation can be calculated. This is the test that actually answers the "which of the three conditions do I have?" question with diagnostic confidence. In Calgary, ambulatory pH monitoring is delivered through the AHS GI services, with Foothills and Rockyview being the most common referral destinations. Wait times depend on triage urgency.

Esophageal manometry

Less commonly the first-line investigation for GERD-pattern symptoms, but added when motility disorders are on the differential. Achalasia, distal esophageal spasm, ineffective esophageal motility, and absent contractility can all produce GERD-overlap presentations and need to be ruled in or out before settling on a functional diagnosis. Manometry is also part of the pre-operative workup if any anti-reflux surgery is being considered.

Why a thorough workup matters before assuming functional causes

Two reasons. First, missing a structural diagnosis that has its own specific treatment is a meaningful clinical error. Eosinophilic esophagitis, Barrett's esophagus, peptic ulcer, eosinophilic gastritis, and esophageal malignancy each have their own management pathways and none of them benefit from a presumed functional label. Second, the patient who carries an unconfirmed GERD label and has not had pH monitoring is in an ambiguous diagnostic state. Treating that ambiguity with a gut-brain therapy on the assumption that it is functional is poor clinical practice, even if the bet often turns out correct. The right sequence is workup first, treatment logic second.

For Calgary patients reading this who have not had a complete workup, the actionable step is a conversation with the GP about whether endoscopy and / or pH monitoring is indicated for their specific picture. For patients who have done the workup and landed in the functional or hypersensitivity territory, the rest of this page becomes more directly relevant.

Before any conversation about advanced therapies, the lifestyle and dietary layer deserves an honest review, because the high-yield interventions are unglamorous but actually do change symptoms for many patients. Most Calgary GERD patients have heard a version of this list before, often in vague form. The version that matters is specific.

Weight management if BMI is elevated

The single best-evidenced lifestyle factor for GERD is weight loss in patients with overweight or obesity. Increased intra-abdominal pressure raises lower esophageal sphincter pressure gradients and contributes mechanically to reflux. Modest weight loss of 5 to 10 percent of body weight has been associated with meaningful symptom improvement in studies of overweight GERD patients. This is worth saying plainly because it tends to get under-emphasised in clinical conversations relative to less impactful interventions.

Elevate the head of the bed for nocturnal symptoms

Patients with predominantly night-time or early-morning reflux symptoms benefit from raising the head of the bed by approximately six inches using risers or a wedge. Pillows alone do not work because they bend the spine without elevating the torso enough to alter reflux mechanics. The intervention is most useful in patients whose symptom pattern is clearly nocturnal.

Avoid late meals

A three-hour gap between the last meal and lying down is the practical guideline. Eating closer to bedtime increases gastric volume and acid secretion at the time the patient is supine, which raises reflux likelihood. For night-shift workers or patients with non-standard schedules the principle is the same: avoid lying down on a full stomach.

Common dietary triggers

Alcohol, chocolate, citrus, caffeine, peppermint, fatty foods, and spicy foods appear repeatedly in trigger lists, with varying individual relevance. The honest position is that universal trigger lists overpromise. Some patients are sensitive to all of them, some to none, most to a subset. A short structured trigger diary across two to four weeks is more useful than blanket avoidance because it shows which foods actually correlate with symptoms for the individual patient.

Low-FODMAP for the GERD-plus-IBS overlap

When GERD-pattern symptoms coexist with IBS, a structured low-FODMAP elimination and reintroduction protocol can be useful for the IBS layer, with potential downstream benefit for upper-GI symptoms in some patients. A randomised trial by Peters 2016 (PMID 27397586) showed gut-directed hypnotherapy and low-FODMAP produced equivalent symptom relief in IBS at six-month follow-up, with no statistically significant difference between arms. The trial was IBS-focused, not GERD-focused, but the takeaway for GERD-plus-IBS patients is that low-FODMAP and gut-directed hypnotherapy are not in opposition; either can work as a primary lever for the IBS dimension, and the gut-brain work additionally targets visceral hypersensitivity that may extend to esophageal symptoms.

What does not help

Some popular interventions have weak or absent supporting evidence and should not replace evidence-based first-line management. Generic "alkaline diets", apple cider vinegar regimens, undifferentiated "gut healing" protocols, and commercial probiotic blends marketed for reflux all sit in this category. The problem is not that they will harm most patients; the problem is opportunity cost. Time spent on these is time not spent on the interventions that are actually supported by reasonable evidence.

Proton pump inhibitors are excellent medications used appropriately and problematic medications used as a default for everything that hurts in the upper GI tract. The honest position requires acknowledging both halves of that statement. Nothing on this page should be read as anti-PPI in the abstract. The point is precision about which patient benefits and which patient is being kept on a long-term medication that is not addressing their actual mechanism.

When PPIs are clearly appropriate

Erosive esophagitis on endoscopy. Barrett's esophagus management. Documented pathological acid exposure on pH monitoring with symptom relief on the medication. Peptic ulcer disease, including H. pylori-associated ulcers as part of an eradication regimen with appropriate antibiotics. Prevention of NSAID-induced ulcers in high-risk patients. Zollinger-Ellison syndrome and other hypersecretory states. In these populations, long-term PPI therapy at the lowest effective dose is supported by the evidence and is the right clinical call.

Where the picture gets murkier

Patients with normal endoscopy, normal acid exposure, and partial or absent PPI response who are nonetheless told to remain on the medication indefinitely. This is the population most likely to have functional heartburn or reflux hypersensitivity, where PPI is not addressing the actual mechanism. The medication is not necessarily harmful, but it is not the right primary lever either, and ongoing reliance on it can delay a more useful conversation about the gut-brain layer.

Long-term PPI considerations

Long-term PPI use has been associated with several considerations worth discussing with the prescribing physician. Reduced absorption of vitamin B12 over long periods. Reduced magnesium absorption with potential for hypomagnesaemia. Modest reductions in calcium absorption with possible bone density implications, particularly in patients already at fracture risk. Microbiome shifts including small-intestinal bacterial overgrowth and altered colonic flora. Potential interactions with other medications metabolised through the same hepatic enzymes. None of these are reasons to stop a clearly indicated PPI. They are reasons to periodically revisit whether the indication is still strong, particularly in patients where the original diagnosis was empirical rather than confirmed.

PPI tapering

Stopping a long-term PPI is not a decision to make abruptly. Acid hypersecretion rebound is well-documented and produces a transient symptomatic flare that can be mistaken for return of the original disease. Tapering should be supervised by the prescribing physician, typically over weeks to months, with step-down from standard to half dose, then to alternate-day dosing, then to as-needed use, with an H2 blocker sometimes used as a bridge during the transition. The point of mentioning this here is so that no patient reads this page and decides independently to stop their PPI. Any change to PPI therapy is a physician decision, not a behavioural one. Hypnotherapy does not prescribe or deprescribe medications.

This is the section where the honest framing matters most, because the temptation to overstate the case is real and the consequences of overstating it are unhelpful. The summary up front: gut-brain therapies have a coherent mechanistic rationale for functional heartburn and reflux hypersensitivity, an emerging direct evidence base in GERD-pattern presentations specifically, and a much stronger evidence base in IBS where the same mechanisms have been studied longer. Treat what follows as a careful description of the territory, not a sales pitch.

The mechanistic rationale

Reflux hypersensitivity and functional heartburn are, mechanistically, visceral hypersensitivity disorders of the esophagus. The same central nervous system pain processing changes that drive visceral hypersensitivity in the colon (the core IBS mechanism) appear to drive analogous hypersensitivity in the esophagus. Heightened spinal and brainstem signalling, altered descending modulation of visceral pain, hypervigilance to upper-GI sensation, conditioned anticipatory responses to meals or specific foods. The detailed pathways and the broader gut-brain axis story are covered elsewhere on the site; the relevant point here is that gut-brain therapies target this layer because medications aimed at the acid layer cannot.

The evidence base

The evidence base for gut-directed hypnotherapy is strongest in IBS. Miller 2015 (PMID 25736234) reported a 76% response rate in 1,000 consecutive refractory IBS patients on the Manchester Protocol, defined as ≥50% improvement on validated symptom scoring. Hasan 2019 (PMID 30702396) reported that 76% of GDH-treated IBS patients maintained symptom improvement at 5+ year follow-up versus 65% in medical-management controls, addressing the durability question that most IBS-focused interventions do not. Peters 2016 (PMID 27397586) demonstrated equivalent symptom relief between gut-directed hypnotherapy and a low-FODMAP diet in a randomised controlled trial of IBS patients, with no statistically significant difference between arms at six-month follow-up.

For GERD specifically, the direct trial evidence is meaningfully thinner. Several small studies of esophageal-directed hypnotherapy in functional heartburn and non-cardiac chest pain have reported promising results, and CBT-for-GERD literature is also emerging. Cognitive behavioural therapy has the broader evidence base for disorders of gut-brain interaction generally, including a large UK randomised trial in IBS reported by Everitt 2019 (PMID 30765267), in which CBT delivered by trained therapists produced clinically significant IBS symptom improvement in 71% of patients. CBT for IBS is now a recommended option in NICE and BSG guidelines and CBT for GERD-pattern presentations is following a similar trajectory in the literature, though more slowly.

The honest position

Gut-directed hypnotherapy as practiced in the Manchester Protocol form is a better-evidenced treatment for IBS than for GERD. That gap is real and saying otherwise is dishonest. What the gut-brain layer for GERD has on its side is a strong mechanistic argument (visceral hypersensitivity is a known driver of functional heartburn and reflux hypersensitivity), a smaller but emerging direct evidence base, and a population (the PPI-failure functional GERD subgroup) for whom the alternative is often nothing. That combination is enough to make the therapy a reasonable thing to try for the right patient, framed correctly. It is not enough to call it a proven first-line treatment for GERD, and any clinician saying otherwise is overstating the literature.

This is also where the comparison with hypnotherapy for functional dyspepsia is worth drawing. FD has a slightly stronger direct hypnotherapy evidence base than GERD-pattern presentations, with two named protocol trials (Calvert and Chiarioni) often cited. The structure of the clinical reasoning is the same in both upper-GI applications: medical pathway is primary, hypnotherapy targets the gut-brain layer that medication does not reach, evidence is smaller than in IBS but mechanism is coherent.

For Calgary patients comparing this with gut-directed hypnotherapy for IBS, the practical message is that the IBS evidence base is larger and more mature. The application to GERD-pattern presentations rides on the shared visceral hypersensitivity mechanism, with the direct GERD trial literature still developing. That is not a reason to dismiss it. It is a reason to frame it accurately.

The clinic offers gut-directed hypnotherapy following the Manchester Protocol, adapted for esophageal and GERD-pattern presentations when a functional component is suspected. The structural mechanics of the program are the same as the IBS program because the underlying gut-brain therapy is the same; the imagery, suggestion content, and symptom tracking are weighted toward upper-GI sensation for GERD-pattern patients.

Format and pricing

$220 CAD per session, with a standard 3-session commitment ($660 CAD total). Sessions are delivered in person at the Calgary location on 4th Ave SW or virtually across Canada, with the same pricing for either format. Continuation beyond the initial three sessions is optional based on clinical progress. There are no admin fees and sessions are paid at time of service. A detailed receipt is provided with the practitioner's ARCH registration number for any reimbursement your insurance provider may approve.

Founder and credentials

The practice is led by Danny M., RCH. A Registered Clinical Hypnotherapist with the Association of Registered Clinical Hypnotherapists (ARCH). The clinical focus is gut-directed hypnotherapy for IBS and related disorders of gut-brain interaction, including the upper-GI extensions to functional dyspepsia and functional GERD-pattern presentations.

Honest framing about fit

For GERD specifically, the practice positions hypnotherapy as a reasonable adjunct to try when PPI has failed and a functional component is suspected, not as an alternative to PPI for documented true GERD. The free fit consultation exists in part to filter for this. Patients who have not yet had the appropriate workup are routed back to their GP or gastroenterologist before any hypnotherapy work begins. Patients on long-term PPI therapy who are wondering whether they still need it are reminded that PPI changes are physician decisions and not something hypnotherapy initiates.

When this is not the right choice

Several scenarios where the answer is not hypnotherapy. Untreated documented erosive GERD or Barrett's esophagus where acid suppression is the indicated treatment. Any alarm features that have not been investigated. No diagnostic workup at all yet. Active eosinophilic esophagitis, peptic ulcer, or other structural disease needing its own treatment. Severe untreated mood or anxiety disorder where psychiatric care is the priority. None of these are hypnotherapy problems, and a fit consultation that ignored these contraindications would not be serving the patient.

Some symptoms patterns are not GERD, are not functional, and need a different pathway with appropriate urgency. The list below is the standard set of upper-GI alarm features taught across gastroenterology references. None of these are hypnotherapy problems. All of them need GP or GI evaluation, and several need same-day or urgent assessment.

Difficulty swallowing (dysphagia)

A new sense that food is sticking, hesitating, or not passing properly through the esophagus is a red flag, particularly when it is progressive (worsening over weeks to months) or includes solids more than liquids. Causes range from peptic stricture and Schatzki ring to eosinophilic esophagitis to esophageal malignancy. None benefit from delay. New dysphagia warrants prompt GP review and usually endoscopy.

Unintentional weight loss

Weight loss that the patient did not deliberately pursue, particularly more than five percent of body weight over three to six months, is a significant alarm feature. In the context of upper-GI symptoms it raises concern for malabsorption, inflammatory disease, and malignancy. This is a workup-needed signal, not a lifestyle conversation.

Persistent vomiting

Vomiting that occurs repeatedly over days or weeks, particularly post-prandially and with retained food, raises concern for gastric outlet obstruction, severe gastroparesis, peptic ulcer, or malignancy. Persistent vomiting needs medical evaluation; it is not within the scope of any hypnotherapy program to treat.

Iron-deficiency anemia

Microcytic anemia on bloodwork in the context of upper-GI symptoms can indicate slow chronic blood loss from the gastrointestinal tract. Common causes include erosive esophagitis, peptic ulcer, gastric malignancy, and small-bowel pathology. Iron-deficiency anemia in a patient with reflux symptoms is a referral-to-GI signal even when other findings are absent.

Overt GI bleeding

Vomiting blood (haematemesis), passing black tarry stools (melena), or fresh bleeding from the upper tract is a medical emergency in most contexts. This warrants immediate care via emergency department or urgent GP assessment, not next-week scheduling. There is no scenario in which the right next step for active upper-GI bleeding is a hypnotherapy session.

Family history of esophageal or gastric cancer

A first-degree family history of upper-GI malignancy lowers the threshold for investigation in any patient with chronic GERD-pattern symptoms. The presence of this history makes endoscopy more strongly indicated and changes the surveillance conversation in patients who do have a confirmed diagnosis. Worth flagging explicitly to the GP.

New onset after age 50 to 55

New-onset upper-GI symptoms in adults over 50 to 55 generally warrant lower threshold for endoscopy than the same symptoms in younger adults, because the pre-test probability of structural and malignant disease is higher in this age group. This is not a hard rule but a useful default; the exact threshold varies by guideline.

The bottom line: red flags are not GERD problems even when they show up alongside GERD-pattern symptoms. Any patient noticing one of these features should have a same-week conversation with their GP at minimum, regardless of how their GERD-style symptoms have been managed up to that point.

The Alberta coverage picture for GERD treatment splits cleanly along medical and non-medical lines. AHCIP covers GP visits, specialist GI consultations, medically-necessary endoscopy, pH monitoring, and inpatient care. Prescription medications including PPIs are typically covered by extended health plans or paid out of pocket depending on the patient's situation. Hypnotherapy sits in a different category.

Hypnotherapy is generally not directly covered under Canadian extended health benefit plans. Some clients can claim related programs (stress management, behavioural change) under a Wellness Spending Account (WSA) if their plan offers one. Coverage rules depend entirely on plan design, so check with your insurance provider before booking.

The reliable next step is to ask three specific questions of the insurance provider: is hypnotherapy or clinical hypnosis a directly eligible expense on the plan, is there a Wellness Spending Account available and what categories does it accept, and what receipt format and provider credentials are required for any claim submission. Sessions at this practice are paid at time of service. A detailed receipt is provided with the practitioner's ARCH registration number. For a more thorough walk-through of the Canadian coverage landscape, see the insurance coverage guide. The principles are identical for GERD-pattern hypnotherapy.